Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028))

Helen Gogas; Reinhard Dummer; Paolo A. Ascierto; Ana Arance; Mario Mandalà; Gabriella Liszkay; Claus Garbe; Dirk Schadendorf; Ivana Krajsová; Ralf Gutzmer; Vanna Chiarion Sileni; Caroline Dutriaux; Naoya Yamazaki; Carmen Loquai; Paola Queirolo; Groot J. de Willem; Abir T. Sellier; Jeanne Suissa; Juliette Murris; Ashwin Gollerkeri; Caroline Robert; Keith T. Flaherty

doi:10.1016/j.ejca.2021.10.002

Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028))

Helen Gogas, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Naoya Yamazaki, Carmen Loquai, Paola Queirolo, Groot J. de Willem, Abir T. Sellier, Jeanne Suissa, Juliette Murris, Ashwin GollerkeriCaroline Robert, Keith T. Flaherty

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret that the second affiliation for Author Paola Queirolo was not included in the published paper. The full author details are given below and have been updated in the online article. Paola Queirolo ^{p, v p} Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy ^v Ospedale Policlinico San Martino IRCCS, Genoa, Italy The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	287-288
Number of pages	2
Journal	European Journal of Cancer
Volume	160
DOIs	https://doi.org/10.1016/j.ejca.2021.10.002
Publication status	Published - 1 Jan 2022

Access to Document

10.1016/j.ejca.2021.10.002

Cite this

Gogas, H., Dummer, R., Ascierto, P. A., Arance, A., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., Yamazaki, N., Loquai, C., Queirolo, P., de Willem, G. J., Sellier, A. T., Suissa, J., Murris, J., ... Flaherty, K. T. (2022). Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028)). European Journal of Cancer, 160, 287-288. https://doi.org/10.1016/j.ejca.2021.10.002

Gogas, Helen ; Dummer, Reinhard ; Ascierto, Paolo A. et al. / Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib : Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028)). In: European Journal of Cancer. 2022 ; Vol. 160. pp. 287-288.

@article{fd56be44bdf74352addb923528f41234,

title = "Corrigendum to {\textquoteleft}Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS){\textquoteright} [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028))",

abstract = "The authors regret that the second affiliation for Author Paola Queirolo was not included in the published paper. The full author details are given below and have been updated in the online article. Paola Queirolo p, v p Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy v Ospedale Policlinico San Martino IRCCS, Genoa, Italy The authors would like to apologise for any inconvenience caused.",

author = "Helen Gogas and Reinhard Dummer and Ascierto, {Paolo A.} and Ana Arance and Mario Mandal{\`a} and Gabriella Liszkay and Claus Garbe and Dirk Schadendorf and Ivana Krajsov{\'a} and Ralf Gutzmer and {Chiarion Sileni}, Vanna and Caroline Dutriaux and Naoya Yamazaki and Carmen Loquai and Paola Queirolo and {de Willem}, {Groot J.} and Sellier, {Abir T.} and Jeanne Suissa and Juliette Murris and Ashwin Gollerkeri and Caroline Robert and Flaherty, {Keith T.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/j.ejca.2021.10.002",

language = "English",

volume = "160",

pages = "287--288",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Gogas, H, Dummer, R, Ascierto, PA, Arance, A, Mandalà, M, Liszkay, G, Garbe, C, Schadendorf, D, Krajsová, I, Gutzmer, R, Chiarion Sileni, V, Dutriaux, C, Yamazaki, N, Loquai, C, Queirolo, P, de Willem, GJ, Sellier, AT, Suissa, J, Murris, J, Gollerkeri, A, Robert, C & Flaherty, KT 2022, 'Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028))', European Journal of Cancer, vol. 160, pp. 287-288. https://doi.org/10.1016/j.ejca.2021.10.002

Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028)). / Gogas, Helen; Dummer, Reinhard; Ascierto, Paolo A. et al.
In: European Journal of Cancer, Vol. 160, 01.01.2022, p. 287-288.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib

T2 - Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028))

AU - Gogas, Helen

AU - Dummer, Reinhard

AU - Ascierto, Paolo A.

AU - Arance, Ana

AU - Mandalà, Mario

AU - Liszkay, Gabriella

AU - Garbe, Claus

AU - Schadendorf, Dirk

AU - Krajsová, Ivana

AU - Gutzmer, Ralf

AU - Chiarion Sileni, Vanna

AU - Dutriaux, Caroline

AU - Yamazaki, Naoya

AU - Loquai, Carmen

AU - Queirolo, Paola

AU - de Willem, Groot J.

AU - Sellier, Abir T.

AU - Suissa, Jeanne

AU - Murris, Juliette

AU - Gollerkeri, Ashwin

AU - Robert, Caroline

AU - Flaherty, Keith T.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The authors regret that the second affiliation for Author Paola Queirolo was not included in the published paper. The full author details are given below and have been updated in the online article. Paola Queirolo p, v p Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy v Ospedale Policlinico San Martino IRCCS, Genoa, Italy The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the second affiliation for Author Paola Queirolo was not included in the published paper. The full author details are given below and have been updated in the online article. Paola Queirolo p, v p Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy v Ospedale Policlinico San Martino IRCCS, Genoa, Italy The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85118336374&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2021.10.002

DO - 10.1016/j.ejca.2021.10.002

M3 - Comment/debate

C2 - 34756500

AN - SCOPUS:85118336374

SN - 0959-8049

VL - 160

SP - 287

EP - 288

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Gogas H, Dummer R, Ascierto PA, Arance A, Mandalà M, Liszkay G et al. Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128] (European Journal of Cancer (2021) 152(116-128) (S0959804921002744), (10.1016/j.ejca.2021.04.028)). European Journal of Cancer. 2022 Jan 1;160:287-288. doi: 10.1016/j.ejca.2021.10.002

Abstract

Access to Document

Other files and links

Cite this